- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 | 2 | GlobeNewswire (USA) | ||
| 28.03. | Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying | 1 | Benzinga.com | ||
| 21.03. | Journey Medical Corp reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 21.03. | Recap: Journey Medical Q4 Earnings | 1 | Benzinga.com | ||
| 21.03. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | Journey Medical GAAP EPS of -$0.21 misses by $0.02, revenue of $79.18M beats by $0.21M | 2 | Seeking Alpha | ||
| 21.03. | Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights | 67 | GlobeNewswire (Europe) | Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings... ► Artikel lesen | |
| 20.03. | Journey Medical FY Earnings Preview | 4 | Seeking Alpha | ||
| 20.03. | Journey Medical Earnings Preview | 1 | Benzinga.com | ||
| 19.03. | Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA | 1 | Zacks | ||
| 18.03. | Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment | 1 | Seeking Alpha | ||
| 18.03. | Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea | 265 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 15.03. | Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 | 1 | GlobeNewswire (USA) | ||
| 13.03. | Journey Medical Corporation to Participate in the 36th Annual ROTH Conference | 1 | GlobeNewswire (USA) | ||
| 11.03. | Journey Medical reports positive Phase 1 trial results for rosacea treatment | 1 | Investing.com | ||
| 11.03. | Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting | 68 | GlobeNewswire (Europe) | Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with... ► Artikel lesen | |
| 26.02. | Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards? | 2 | Zacks | ||
| 05.01. | Journey Medical Submits NDA For DFD-29 To FDA For Treatment Of Rosacea In Adults | 2 | RTTNews | ||
| 05.01. | Journey Medical submits NDA for DFD-29 for rosacea | 1 | Seeking Alpha | ||
| 05.01. | Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea | 502 | GlobeNewswire (Europe) | If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea NDA submission supported by positive Phase... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 61,37 | +0,38 % | Gilead Sciences Aktie: Umsatzeinbußen vorhergesagt | Gilead Sciences, ein führendes Biotechnologieunternehmen, steht vor der Bekanntgabe seiner Ergebnisse für das erste Quartal 2024 am 25. April nach Börsenschluss. Die Umsatzprognosen deuten auf leichte... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 371,55 | +0,04 % | Vertex Pharmaceuticals: Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older | KALYDECO is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - Vertex Pharmaceuticals... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 15,545 | -0,54 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,000 | +7,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| OPKO HEALTH | 1,164 | -0,82 % | OPKO Health, Inc.: AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV | • Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies... ► Artikel lesen | |
| EXSCIENTIA | 3,860 | +2,66 % | Exscientia plc - 6-K, Report of foreign issuer | ||
| JAZZ PHARMACEUTICALS | 102,00 | -0,29 % | Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community | Originally published by Jazz PharmaceuticalsNORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Purple Day spotlights epilepsy and the challenges that people face when living with the condition.Jazz wants... ► Artikel lesen | |
| ROYALTY PHARMA | 25,850 | -1,22 % | Dividendenbekanntmachungen (15.02.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 1,51 USD 1,4074 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0559 EUR ADVANCED ENERGY INDUSTRIES INC US0079731008 0... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 13,925 | +2,31 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
| CATALENT | 52,19 | -0,13 % | Aktien Europa: Moderate Gewinne zum Start in geldpolitisch wichtige Woche | PARIS/LONDON (dpa-AFX) - Gestützt von rekordhohen US-Börsen sind Europas wichtigste Aktienmärkte am Montag freundlich in neue Handelswoche gestartet. Nachdem der EuroStoxx 50 schon vor dem Wochenende... ► Artikel lesen | |
| SOLIGENIX | 0,415 | -2,81 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| AYTU BIOPHARMA | 2,680 | 0,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 | Webcasted presentation to take place at 4:40 p.m. Eastern timeDENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 30,200 | -6,21 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update | Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study... ► Artikel lesen | |
| ROCKET LAB USA | 3,510 | -0,28 % | How Rocket Lab Outgrew Billionaire Elon Musk's Space Company in Q1 | ||
| TITAN PHARMACEUTICALS | 6,630 | 0,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria | SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-2,86 %) liegt der Kurs bei 3,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
